β-3肾上腺素受体激动剂治疗膀胱过度活动症的研究进展  

Progress of β3-Adrenoceptor Agonists in the Treatment of the Overactive Bladder

作　　者：邓小林[1] 陈伟豪[2] 关志忱[3] 

机构地区：[1]赣州市人民医院,江西赣州341000 [2]汕头大学医学院第一附属医院 [3]北京大学深圳医院泌尿外科

出　　处：《天津医药》2014年第3期285-287,共3页Tianjin Medical Journal

摘　　要：膀胱过度活动症(OAB)是一种常见多发疾病,其治疗主要是保守治疗,抗毒蕈碱药是目前治疗OAB的一线药物。但抗毒蕈碱药对于部分OAB无效,而且该类药物的不良反应限制了其广泛应用。近年来,随着OAB病理机制的深入研究,大量基础和临床研究证实β3-肾上腺素受体(β-3AR)激动剂有望成为治疗OAB的一类新药。本文就β-3AR激动剂的药理特征、有效性、安全性和耐受性进行综述。The overactive bladder syndrome （OAB） is a prevalent condition among adults. Currently, the present treatment is mainly conservative therapy. Antimuscarinic drugs are currently the first-line treatment for OAB. However, many patients experienced insufficient therapeutic benefit and/or unpleasant side effects. Recent advances in the understand-ing of the physiopathology of OAB have driven a huge amount of basic and clinical research into novel pharmacological com-pounds.β3-adrenoceptor agonists are an emerging drug class for the treatment of the OAB. This study reviewed the pharma-cological profile ofβ3-adrenoceptor agonists and discussed the efficacy, safety and tolerability.

关 键 词：肾上腺素能Β激动剂 膀胱 过度活动性 综述 

分 类 号：R738.1[医药卫生—肿瘤]